A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase II Study to Evaluate the Safety and Efficacy and Dose Response of 28 Days of Once-Daily Dosing of the Oral Motilin Receptor Agonist GSK962040, in Type I and II Diabetic Male and Female Subjects With Gastroparesis.

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase II Study to Evaluate the Safety and Efficacy and Dose Response of 28 Days of Once-Daily Dosing of the Oral Motilin Receptor Agonist GSK962040, in Type I and II Diabetic Male and Female Subjects With Gastroparesis.

Completed
Phase of Trial: Phase II

Latest Information Update: 20 Nov 2017

At a glance

  • Drugs Camicinal (Primary)
  • Indications Diabetic gastroparesis
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Feb 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 03 Aug 2012 Planned end date changed from 1 Oct 2012 to 1 Mar 2013 as reported by ClinicalTrials.gov.
    • 27 Jan 2012 Planned end date changed from 1 Feb 2012 to 1 Oct 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top